The publication of this special issue on diabetes in this journal is the last of a series of events making 2019 the Year of Cardio-diabetology.
Launched under the joint initiative of the European Association of Preventive Cardiology (EAPC) and European Society of Cardiology (ESC), this supplement issue is part of a comprehensive educational programme to improve the knowledge on the management of patients with diabetes and their cardiovascular complications. It has been elaborated with the partnership of the Study Group on Diabetes and Cardiovascular Disease of the European Association for the Study of Diabetes (EASD). Experts from the ESC Council for Cardiology Practice (CCP), Association of Cardiovascular Nursing and Allied Professions (ACNAP), ESC Working Group on Aorta and Peripheral Vascular Disease, ESC Working Group on Myocardial and Pericardial Diseases and ESC Working Group on Thrombosis were also involved in all stages of the programme development. The programme was timely planned in order to promote and facilitate the implementation of the recently released ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases elaborated in collaboration with the EASD. 1 These guidelines have been released during the last ESC congress in Paris, and were highly awaited following the recent publication of a series of trials with new glucoselowering drugs showing their benefits in improving the cardiovascular outcomes of diabetes patients.
The global epidemic of diabetes is a serious public health concern with a dramatic burden on quality of life and health expenditure, highlighted by Strandl et al. in this issue. 2 Almost one out of every three patients managed by cardiologists is (pre)diabetic, and the relative paucity of diabetologists in many countries as compared to the growing population of patients should push the cardiovascular specialists to initiate glucoselowering drugs, similar to what we already do for dyslipidaemia. In this issue, Prattichizzo et al. 3 update us on all we need to know about the benefits (or harmlessness) of the different agents, and Valensi et al. 4 summarise the evidence on glucose levels and cardiovascular outcomes.
This special issue accompanies the cardiovascular specialists from the pre-diabetic state (see the updated evidence in the paper by Beulens et al.), 5 to the holistic approach of the management of diabetes (see Ryde´n et al.) 6 and the metabolic syndrome (see Nilsson et al.) , 7 up to the management of those experiencing a cardiovascular event. It is now well accepted that the outcome of patients with coronary artery disease (CAD) and/or heart failure (HF) is improved when they are managed through a rehabilitation programme. In a very comprehensive document, Hansen et al. 8 provide a clear roadmap on the optimal management of diabetes patients in rehabilitation programmes.
The biological link between diabetes and atherosclerosis may be somehow complex for clinicians. In this issue La Sala et al. masterfully provide an accessible summary of the pathways making diabetes one of the major risk factors for atherosclerotic disease. 9 Readers can then follow the paper by Dal Canto et al., who nicely put all the large and small vessel complications of diabetes in a single review. 10 The paper illustrates the need for a comprehensive and integrative management of the cardiovascular complications of diabetes.
Patients with diabetes and CAD need special attention as their outcomes also depend on adequate, and sometimes specific, strategies of revascularisation and antithrombotic therapies. The readers are invited to refer to Rocca et al., who tackle these specific issues, reminding us of the particularities of platelet activity in these patients and the potential consequences for their management. 11 While diabetes is associated with all patterns of atherosclerotic disease, lower-extremity artery disease (LEAD) has among all the strongest association with diabetes, and almost half of the patients hospitalised for LEAD have diabetes. Similar to CAD, the presence of diabetes in LEAD represents particular prognostic information, with poorer outcomes after revascularisation and increased rates of amputation. Mazzolai et al. propose a comprehensive review on this important topic. 12 While traditionally the arterial complications of diabetes are well known and are subject to regular screening, HF in these patients is a growing challenge. Almost one out of five diabetes patients have or will have HF, with high rates of unknown HF, emphasising the need for a more systematic approach in the screening of this condition. Beyond the classic purveyors of HF (i.e. hypertension, CAD and renal disease) frequent in diabetes patients, specific metabolic abnormalities are identified in the myocardium, supporting the concept of diabetic cardiomyopathy. In this issue, Ferrini et al. go through updated data regarding the interrelations between diabetes and HF and its complications. 13 Overall, the management of diabetes and its cardiovascular complications has thoroughly advanced in this new century. Nijpels et al. give us an overview on the modern management of patients with diabetes, going through all the innovations. 14 Patients have also evolved, and all this management progress and innovation mandate putting patients in the centre and making them active players in care. The contribution of Lembrinou et al. 15 invites us to implement this patient-centred approach in such a chronic disease, for the best implementation of guideline-advocated therapies.
